title: [Treatment of drooling in patients with parkinsonism].
abstract: Between 50% and 60% of patients with parkinsonism suffer from severe drooling (sialorrhoea). Sialorrhoea is a major social problem with medical risks as well, e.g. aspiration pneumonia. Sialorrhoea is not caused by increased production of saliva, but by impaired swallowing, leading to storage of saliva in the anterior part of the mouth. Sialorrhoea can be treated by anticholinergics, botulinum toxin injections, surgery and radiotherapy of the salivary glands. The optimal treatment of sialorrhoea needs to be determined individually, for which a decision tree is available.
authors.affiliation: Universitair Medisch Centrum Groningen, afd. Neurologie, Groningen, The Netherlands.
authors.forename: Marieke
authors.initials: M
authors.lastname: van Onna
authors.forename: Teus
authors.initials: T
authors.lastname: van Laar
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000150:complications*; D018579:Patient Selection; D011015:Pneumonia, Aspiration / Q000517:prevention & control; D012798:Sialorrhea / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D018680:Cholinergic Antagonists; D019274:Botulinum Toxins, Type A